Sivia Capital Partners LLC Buys 3,419 Shares of IQVIA Holdings Inc. $IQV

Sivia Capital Partners LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 89.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,235 shares of the medical research company’s stock after purchasing an additional 3,419 shares during the period. Sivia Capital Partners LLC’s holdings in IQVIA were worth $1,631,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares during the period. Geode Capital Management LLC lifted its position in IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares during the period. Alliancebernstein L.P. lifted its position in IQVIA by 1.2% during the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares during the period. Boston Partners bought a new position in IQVIA during the third quarter valued at approximately $676,698,000. Finally, Artisan Partners Limited Partnership lifted its position in IQVIA by 4.9% during the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. UBS Group lowered their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Jefferies Financial Group lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a report on Friday, March 6th. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a report on Friday, February 6th. Finally, Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $224.13.

IQVIA Stock Up 0.8%

Shares of IQV stock opened at $182.12 on Thursday. IQVIA Holdings Inc. has a 12 month low of $143.00 and a 12 month high of $247.04. The stock has a market cap of $30.40 billion, a P/E ratio of 22.57, a P/E/G ratio of 1.73 and a beta of 1.21. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a 50 day simple moving average of $171.35 and a two-hundred day simple moving average of $195.26.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the company earned $2.70 earnings per share. The firm’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 11.58 earnings per share for the current year.

IQVIA announced that its Board of Directors has approved a stock buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.